Victoria Federico Paly (Victoria F Paly)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 16

Top Topics

Metastatic Colorectal Cancer

Mesenchymal Stem Cells

Top Venues

International journal of chronic obstructive pulmonary disease

Journal of comparative effectiveness research

Journal of medical economics

MDM policy & practice

This page only lists publications with an associated author ORCID identifier.

Publications

Victoria Federico Paly, Arvind Dasari, Joleen Hubbard, Tanios Bekaii-Saab, Thihan Padukkavidana, Luis G Hernandez
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US. Journal of comparative effectiveness research 13 (8) (2024)
Victoria Federico Paly, Shujun Li, Pratishtha Khanduri, Alemseged Ayele Asfaw, Denise Zou, Luis G Hernandez
Budget impact analysis of introducing fruquintinib for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the United States from the payer perspective. Journal of medical economics (2024)
Victoria Federico Paly, Arvind Dasari, Joleen Hubbard, Tanios Bekaii-Saab, Thihan Padukkavidana, Luis G Hernandez
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US. Journal of comparative effectiveness research 13 (8) (2024)
Victoria Federico Paly, Arvind Dasari, Joleen Hubbard, Tanios Bekaii-Saab, Thihan Padukkavidana, Luis G Hernandez
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US. Journal of comparative effectiveness research 13 (8) (2024)
Victoria Federico Paly, Arvind Dasari, Joleen Hubbard, Tanios Bekaii-Saab, Thihan Padukkavidana, Luis G Hernandez
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US. Journal of comparative effectiveness research 13 (8) (2024)
Victoria Federico Paly, Shujun Li, Pratishtha Khanduri, Alemseged Ayele Asfaw, Denise Zou, Luis G Hernandez
Budget impact analysis of introducing fruquintinib for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and biologics in the United States from the payer perspective. Journal of medical economics 27 (1) (2024)
Victoria Federico Paly, Arvind Dasari, Joleen Hubbard, Tanios Bekaii-Saab, Thihan Padukkavidana, Luis G Hernandez
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US. Journal of comparative effectiveness research (2024)
Victoria Federico Paly, Murat Kurt, Lirong Zhang, Marcus O Butler, Olivier Michielin, Adenike Amadi, Emma Hernlund, Helen M Johnson, Srividya Kotapati, Andriy Moshyk, John Borrill
Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma. MDM policy & practice 7 (1) (2022)
Victoria Federico Paly, Laura Amanda Vallejo-Aparicio, Alan A Martin, José Luis Izquierdo, Juan Antonio Riesco Miranda, Juan José Soler-Cataluña, Catarina Abreu, Chandroday Biswas, Afisi S Ismaila
Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial. International journal of chronic obstructive pulmonary disease 17 (2022)
Victoria Federico Paly, Laura Amanda Vallejo-Aparicio, Alan A Martin, José Luis Izquierdo, Juan Antonio Riesco Miranda, Juan José Soler-Cataluña, Catarina Abreu, Chandroday Biswas, Afisi S Ismaila
Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial. International journal of chronic obstructive pulmonary disease 17 (2022)
Victoria Federico Paly, Laura Amanda Vallejo-Aparicio, Alan A Martin, José Luis Izquierdo, Juan Antonio Riesco Miranda, Juan José Soler-Cataluña, Catarina Abreu, Chandroday Biswas, Afisi S Ismaila
Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial. International journal of chronic obstructive pulmonary disease 17 (2022)
Victoria Federico Paly, Laura Amanda Vallejo-Aparicio, Alan A Martin, José Luis Izquierdo, Juan Antonio Riesco Miranda, Juan José Soler-Cataluña, Catarina Abreu, Chandroday Biswas, Afisi S Ismaila
Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial. International journal of chronic obstructive pulmonary disease 17 (2022)
Victoria Federico Paly, Laura Amanda Vallejo-Aparicio, Alan A Martin, José Luis Izquierdo, Juan Antonio Riesco Miranda, Juan José Soler-Cataluña, Catarina Abreu, Chandroday Biswas, Afisi S Ismaila
Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial. International journal of chronic obstructive pulmonary disease 17 (2022)
Andrea Gabrio, Necdet B Gunsoy, Gianluca Baio, Alan A Martin, Victoria Federico Paly, Nancy Risebrough, David M G Halpin, Dave Singh, Robert A Wise, MeiLan K Han, Fernando J Martinez, Gerard J Criner, Neil Martin, David A Lipson, Afisi S Ismaila
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial. International journal of chronic obstructive pulmonary disease 17 (2022)
Victoria Federico Paly, Yusuke Hikichi, Timothy Baker, Eijun Itakura, Nisha Chandran, James Harrison
Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan. Journal of medical economics 23 (12) (2020)
Victoria Federico Paly, Ian P Naya, Necdet B Gunsoy, Maurice T Driessen, Nancy A Risebrough, Andrew Briggs, Afisi S Ismaila
Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study. International journal of chronic obstructive pulmonary disease 14 (2019)